Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Pharmacogenetics and Pharmacogenomics: Overview01:29

Pharmacogenetics and Pharmacogenomics: Overview

Pharmacogenetics and pharmacogenomics examine how genetic factors influence an individual's response to drugs. While pharmacogenetics focuses on the impact of specific genetic variants on drug effects, pharmacogenomics takes a broader approach, studying how genetic variation across populations contributes to differences in drug responses. These fields aim to explain why individuals may experience varying levels of efficacy or adverse reactions to the same medication.Variability in drug...
Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Principles of Pharmacogenetics: Types of Genetic Variants01:27

Principles of Pharmacogenetics: Types of Genetic Variants

The human genome is over 99.9% identical between individuals, yet genetic differences exist at millions of bases. The human genome contains approximately 3 million variant positions per individual, many of which are heterozygous, contributing to genetic diversity and individual traits. Genetic variations include single-nucleotide polymorphisms (SNPs), insertions, deletions, and copy number variations (CNVs).SNPs, the most common variation, involve single-base changes in DNA. These can be...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes01:28

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450 isoenzymes,...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Low-dose digoxin in patients with heart failure with reduced or mildly reduced ejection fraction: a randomized controlled trial.

Nature medicine·2026
Same author

Symptom Burden and Patient-Reported Outcomes in Kidney Transplant Recipients: Results From the TransplantLines Biobank and Cohort Studies.

Kidney medicine·2026
Same author

The Impact of Fluvoxamine on Clozapine and Norclozapine Serum Concentrations.

European journal of drug metabolism and pharmacokinetics·2025
Same author

Placental slice techniques in physiology, pathophysiology, and toxicology: A systematic review with a focus on precision-cut slices.

Placenta·2025
Same author

The influence of female sex and estrogens on drug pharmacokinetics: what is the evidence?

Expert opinion on drug metabolism & toxicology·2025
Same author

A method to measure renal inner medullary perfusion using MR renography.

Magma (New York, N.Y.)·2025

Related Experiment Video

Updated: Jul 7, 2026

Infinium Assay for Large-scale SNP Genotyping Applications
13:33

Infinium Assay for Large-scale SNP Genotyping Applications

Published on: November 19, 2013

Pharmacogenetics: from bench to byte.

J J Swen1, I Wilting, A L de Goede

  • 1Department of Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, The Netherlands.

Clinical Pharmacology and Therapeutics
|February 7, 2008
PubMed
Summary

Pharmacogenetic testing shows limited clinical use due to insufficient evidence of improved outcomes and interpretation challenges. Guidelines are needed to integrate pharmacogenetic results into clinical practice for better drug therapy.

More Related Videos

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Related Experiment Videos

Last Updated: Jul 7, 2026

Infinium Assay for Large-scale SNP Genotyping Applications
13:33

Infinium Assay for Large-scale SNP Genotyping Applications

Published on: November 19, 2013

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease
09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

Area of Science:

  • Pharmacogenetics
  • Clinical Pharmacology
  • Genomic Medicine

Background:

  • Pharmacogenetic testing adoption is limited, primarily in oncology and psychiatry.
  • Lack of robust scientific evidence demonstrating improved clinical outcomes hinders widespread use.
  • Complexity in interpreting pharmacogenetic test results, especially for cytochrome P450 enzyme variants, poses challenges for healthcare professionals.

Purpose of the Study:

  • To address the limited clinical utility of pharmacogenetics.
  • To highlight the need for evidence-based guidelines linking pharmacogenetic results to therapeutic recommendations.
  • To discuss barriers in integrating pharmacogenetic information into routine clinical decision-making.

Main Methods:

  • Review of existing literature on pharmacogenetics and clinical outcomes.
  • Analysis of challenges in interpreting pharmacogenetic test results for physicians and pharmacists.
  • Examination of the availability and accessibility of clinical guidelines for pharmacogenetic testing.

Main Results:

  • Scientific evidence supporting improved clinical outcomes from pharmacogenetic testing is scarce.
  • Physicians and pharmacists require specialized pharmacological knowledge to interpret test results effectively.
  • Existing guidelines, like those for antidepressant therapy involving CYP2D6, are not readily accessible in clinical workflows.

Conclusions:

  • Widespread clinical application of pharmacogenetics is hampered by a lack of outcome data and interpretation difficulties.
  • Development and integration of accessible clinical guidelines are crucial for the effective use of pharmacogenetics.
  • Bridging the gap between pharmacogenetic research and clinical practice is essential for personalized medicine.